Inotiv, Inc. (NASDAQ: NOTV) reported a 23.5% increase in revenue to $130.7 million for the third quarter of fiscal 2025, with year-to-date revenue up 4.0% to $374.9 million. The company’s conference call is scheduled for today at 4:30 pm ET.

During the third quarter, DSA net awards increased by 25% year-over-year, primarily due to business growth in Discovery, Medical Device, Biotherapeutics, and Genetic Toxicology. Inotiv remains focused on client satisfaction and delivering high-quality products and services.

Inotiv’s Q3 FY 2025 highlights include a $24.9 million increase in revenue compared to Q3 FY 2024. The company reported a consolidated net loss of $17.6 million, with Adjusted EBITDA at $11.6 million.

For the nine months ended June 30, 2025, Inotiv’s revenue increased by 4.0% to $374.9 million, with a consolidated net loss of $60.1 million. Adjusted EBITDA for the period was $22.1 million.

Cash and cash equivalents for Inotiv were $6.2 million as of June 30, 2025, compared to $21.4 million on September 30, 2024. The company also requested a draw of $3.0 million on its revolving credit facility.

Inotiv will host a conference call on August 6, 2025, at 4:30 pm ET to discuss its third fiscal quarter of 2025 results. Interested parties can participate by dialing (800) 245-3047 (Domestic) or (203) 518-9765 (International) with the Conference ID “INOTIV”.

Adjusted EBITDA for Inotiv was $11.6 million for the third quarter of fiscal 2025, representing 8.9% of total revenue. Adjusted EBITDA provides useful information for evaluating the company’s ongoing operations and financial performance.

Read more at GlobeNewswire: CORRECTING and REPLACING – Inotiv Reports Third Quarter